Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) has issued an update.
NeuroScientific Biopharmaceuticals Ltd has completed the acquisition of Isopogen WA Ltd, gaining full rights to the StemSmart™ patented stem cell technology. This acquisition positions the company to focus on the Special Access Program for fistulising Crohn’s disease, aiming to provide alternative treatments with fewer side effects. Early trials indicate promising results in treating refractory Crohn’s disease and steroid-refractory GVHD, suggesting potential for improved patient outcomes. The recent FDA approval of a similar MSC therapy has bolstered confidence and investment in this field, potentially enhancing NeuroScientific’s market positioning.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Ltd is a company operating in the biopharmaceutical industry, focusing on developing advanced stem cell therapies. Their primary product, StemSmart™ Mesenchymal Stem Cells (MSC), is derived from adult human donor bone marrow and is designed to improve clinical efficacy in treating various conditions. The company is particularly focused on addressing diseases such as Crohn’s disease, GVHD, and other severe health conditions with significant market potential.
Average Trading Volume: 388,302
Technical Sentiment Signal: Buy
Current Market Cap: A$58.2M
For a thorough assessment of NSB stock, go to TipRanks’ Stock Analysis page.